These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 32964648)

  • 1. Overall hemostasis potential and aPTT-clot waveform analysis as powerful laboratory diagnostic tools for identification of hemophilia A patients with unexpected bleeding phenotype.
    Milos M; Coen Herak D; Mahmoud Hourani Soutari N; Pavic J; Zupancic-Salek S; Zadro R; Antovic JP
    Int J Lab Hematol; 2021 Apr; 43(2):273-280. PubMed ID: 32964648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of activated partial thromboplastin time clot waveform analysis and thrombin generation test in the evaluation of bleeding phenotype in Hemophilia A.
    Dave RG; Geevar T; Mammen JJ; Vijayan R; Mahasampath G; Nair SC
    Indian J Pathol Microbiol; 2021; 64(1):117-122. PubMed ID: 33433420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New quantitative aPTT waveform analysis and its application in laboratory management of haemophilia A patients.
    Milos M; Coen Herak D; Zupancic-Salek S; Zadro R
    Haemophilia; 2014 Nov; 20(6):898-904. PubMed ID: 25273337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab.
    Nogami K; Matsumoto T; Tabuchi Y; Soeda T; Arai N; Kitazawa T; Shima M
    J Thromb Haemost; 2018 Jun; 16(6):1078-1088. PubMed ID: 29645406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile.
    Santagostino E; Mancuso ME; Tripodi A; Chantarangkul V; Clerici M; Garagiola I; Mannucci PM
    J Thromb Haemost; 2010 Apr; 8(4):737-43. PubMed ID: 20102490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal monitoring of bypass therapy in hemophilia A patients with inhibitors by the use of clot waveform analysis.
    Haku J; Nogami K; Matsumoto T; Ogiwara K; Shima M
    J Thromb Haemost; 2014; 12(3):355-62. PubMed ID: 24354697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing thrombin generation in patients with hemophilia A and patients on vitamin K antagonists.
    de Koning MLY; Fischer K; de Laat B; Huisman A; Ninivaggi M; Schutgens REG
    J Thromb Haemost; 2017 May; 15(5):868-875. PubMed ID: 28296129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clot waveform analysis using CS-2000i™ distinguishes between very low and absent levels of factor VIII activity in patients with severe haemophilia A.
    Matsumoto T; Nogami K; Tabuchi Y; Yada K; Ogiwara K; Kurono H; Arai N; Shima M
    Haemophilia; 2017 Sep; 23(5):e427-e435. PubMed ID: 28750470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A ROTEM method using APTT reagent and tissue factor as the clotting activators may better define bleeding heterogeneity in moderate or severe haemophilia A (part I: Study in plasma samples).
    He S; Eelde A; Petrini P; Wallen H; Gabrielsson L; Svensson J; Blombäck M; Holmström M
    Thromb Res; 2018 Nov; 171():7-13. PubMed ID: 30216822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Assessment of Factor VIII Activity by Template Matching Utilizing Weighted Average Parameters from Comprehensive Clot Waveform Analysis.
    Shimonishi N; Ogiwara K; Oda Y; Kawabe T; Okazaki S; Shima M; Nogami K
    Thromb Haemost; 2021 Feb; 121(2):164-173. PubMed ID: 32828071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two global haemostatic assays as additional tools to monitor treatment in cases of haemophilia A.
    Antovic JP; Mikovic D; Elezovic I; Holmström M; Wilkens M; Elfvinge P; Mahmoud Hourani Soutari N; Antovic A
    Thromb Haemost; 2012 Jul; 108(1):21-31. PubMed ID: 22534727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A combined approach using global coagulation assays quickly differentiates coagulation disorders with prolonged aPTT and low levels of FVIII activity.
    Matsumoto T; Nogami K; Shima M
    Int J Hematol; 2017 Feb; 105(2):174-183. PubMed ID: 27730530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the phenotypic severity of hemophilia A: using rotational thromboelastometry (ROTEM) and APTT-clot waveform analysis.
    Gupta D; Arya V; Dass J; Gupta N; Kalra M; Sachdeva A; Kotwal J
    Blood Res; 2024 May; 59(1):19. PubMed ID: 38743166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clot waveform analysis for perioperative hemostatic monitoring in a hemophilia A patient on emicizumab undergoing liver transplantation.
    Awane M; Wakui M; Ozaki Y; Kondo Y; Oka S; Fujimori Y; Yatabe Y; Arai T; Yamada Y; Hori S; Obara H; Hasegawa Y; Matsushita H
    Clin Chim Acta; 2023 Apr; 544():117339. PubMed ID: 37076096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The activated partial thromboplastin time-clot waveform analysis in hemophilia: Does it help in differentiation?
    Mannan KA; Kumar N; Ahluwalia J; Hans C; Kler A; Prakash G; Jain R
    Int J Lab Hematol; 2023 Apr; 45(2):241-249. PubMed ID: 36495061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.
    Zollner SB; Raquet E; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
    Thromb Res; 2013 Aug; 132(2):280-7. PubMed ID: 23830969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mild hemophilia A.
    Franchini M; Favaloro EJ; Lippi G
    J Thromb Haemost; 2010 Mar; 8(3):421-32. PubMed ID: 19995408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges in the laboratory analyses of bleeding disorders.
    Chitlur M
    Thromb Res; 2012 Jul; 130(1):1-6. PubMed ID: 22483776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of Comprehensive Coagulation Assays Reflecting the Clinical Phenotype].
    Matsumoto T; Nogami K
    Rinsho Byori; 2017 Feb; 65(2):153-159. PubMed ID: 30762981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients.
    Nakajima Y; Mizumachi K; Shimonishi N; Furukawa S; Yada K; Ogiwara K; Takeyama M; Shima M; Nogami K
    Int J Hematol; 2022 Apr; 115(4):489-498. PubMed ID: 35043383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.